A Histologic Study of Imatinib Cardiotoxicity in Adult Male Rats

Luma Al-Allaf; Wahda Alnuaeimy

doi:10.3889/oamjms.2023.8826

Authors

Luma Al-Allaf Department of Anatomy, College of Medicine, University of Mosul, Mosul, Iraq https://orcid.org/0000-0002-8706-3068
Wahda Alnuaeimy Department of Pathology, College of Medicine, University of Mosul, Mosul, Iraq

DOI:

https://doi.org/10.3889/oamjms.2023.8826

Keywords:

Cardiotoxicity, Oxidative stress, rat, Histopathology

Abstract

BACKGROUND: Cardiotoxicity is an unanticipated adverse effect associated with some chemotherapeutic agents. There are conflicting results about imatinib-induced cardiac toxicity.

AIM: This study aims at investigating the possible cardiotoxic effects of imatinib in rat model through assessing the possible histopathological alterations that might develop.

MATERIALS AND METHODS: This is a case–control and experimental study conducted over a period of 3 months at laboratory of postgraduate studies, Department of Anatomy, College of Medicine, University of Mosul, Mosul, Northern Iraq. Sixteen adult male Albino rats were randomly assigned to either “control group” or “imatinib-treated group.” The control group was gavaged with distilled water daily for 4 weeks while the second group was given oral imatinib (200 mg/kg/day) for the same duration. Animals were sacrificed by euthanization after 24 h of the last dose. Hearts were obtained and cardiac specimens were immersed in paraffin. Sections’ staining by hematoxylin (Harris)-eosin (H&E) and Massons’ Thrichrom.

RESULTS: Rats treated with imatinib showed decreased physical activity and food intake. Regular arrangements of myofilaments were noticed during light microscopic examination of cardiac sections of control rats. However, sections from imatinib group showed several histological alterations (mainly myofibrillar loss in myocardium with vacuolated cytoplasm). Necrosis of cardiac muscle fibers was also noticed in some sections. Appearance of deeply staining cells with pyknotic nucleus, in addition to shrinkage of cardiac muscle fibers, was also noticed in some sections. The mean score of cardiac injury in the treated group was 2.1 (vs. 0.6 in controls). Some sections of treated group showed an increment (mild) in collagen fibers in-between cardiac myocytes.

CONCLUSIONS: The observations concluded that imatinib has targeted action on cardiomyocytes. Oncologists should be cautious regarding imatinib dose and duration besides the close cardiac monitoring throughout and beyond therapy duration.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

Author Biography

Wahda Alnuaeimy, Department of Pathology, College of Medicine, University of Mosul, Mosul, Iraq

Professor, Department of Pathology, College of Medicine, University of Mosul, Mosul, Iraq

References

Howell ST, Shalet SM. Testicular function following chemotherapy. Hum Reprod Update. 2001;7(4):363-9. https://doi.org/10.1093/humupd/7.4.363 PMid:11476348

Saad SY, Alkharfy KM, Arafah MM. Cardiotoxic effects of arsenic trioxide/imatinib mesilate combination in rats. J Pharm Pharmacol. 2006;58(4):567-73. https://doi.org/10.1211/ jpp.58.4.0017 PMid:16597375

Maharsy W, Aries A, Mansour O, Komati H, Nemer M. Ageing is a risk factor in imatinib mesylate cardiotoxicity. Eur J Heart Fail.

;16(4):367-76. https://doi.org/10.1002/ejhf.58 PMid:24504921

Goldman JM, Melo JV. Chronic myeloid leukemia-advances in biology and new approaches to treatment. N Engl J Med.

;349(15):1451-64. https://doi.org/10.1056/NEJMra020777 PMid:14534339

Nadal, E, Olavarria E. Imatinib mesylate (Gleevec/Glivec) a molecular-targeted therapy for chronic myeloid leukemia and other malignances. Int J Clin Pract. 2004;58(5):511-6. https://doi.org/10.1111/j.1368-5031.2004.00173.x PMid:15206509

Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer. 2007;7(5):332-44. https://doi.org/10.1038/nrc2106 PMid:17457301

Hahn EA, Glendenning GA, Sorensen MV, Hudgens SA, Druker BJ, Guilhot F, et al. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: Results from the IRIS Study. J Clin Oncol. 2003;21(11):2138-46. https://doi.org/10.1200/JCO.2003.12.154 PMid:12775739

Wolf A, Couttet P, Dong M, Grenet O, Heron M, Junker U, et al. Imatinib does not induce cardiotoxicity at clinically relevant concentrationsinpreclinicalstudies.LeukRes.2010;34(9):1180-8. https://doi.org/10.1016/j.leukres.2010.01.004 PMid:20122731

Ilbey YO, Ozbek E, Cekmen M, Simsek A, Otunctemur A, Somay A. Protective effect of curcumin in cisplatin-induced oxidative injury in rat testis: Mitogen-activated protein kinase and nuclear factor-kappa B signaling pathways. Hum Reprod. 2009;24(7):1717-25. https://doi.org/10.1093/humrep/dep058 PMid:19279034

Herman EH, Knapton A, Rosen E, Thompson K, Rosenzweig B, Estis J, et al. A multifaceted evaluation of imatinib-induced cardiotoxicity in the rat. Toxicol Pathol. 2011;39(7):1091-106. https://doi.org/10.1177/0192623311419524 PMid:21937741

Swamy AH, Patel UM, Koti BC, Gadad PC, Patel NL, Thippeswamy AH. Cardioprotective effect of Saraca indica against cyclophosphamide induced cardiotoxicity in rats: A biochemical, electrocardiographic and histopathological study. Indian J Pharmacol. 2013;45(1):44-8. https://doi.org/10.4103/0253-7613.106434 PMid:23543849

Mohan M, Bhandare S. Protective effect of Solanum torvum against testicular toxicity in male Wistar rats. Int J Pharm Pharm Sci. 2012;4(3):188-92.

Favareto AP, Fernandez CD, da Silva DA, Anselmo-Franci JA, De Grava Kempinas W. Persistent impairment of testicular histology and sperm motility in adult rats treated with Cisplatin at peri-puberty. Basic Clin Pharmacol Toxicol. 2011;109(2):85-96. https://doi.org/10.1111/j.1742-7843.2011.00688.x PMid:21410649

Abarikwu SO, Otuechere CA, Ekor M, Monwuba K, Osobu D. Rutin ameliorates cyclophosphamide-induced reproductive toxicity in male rats. Toxicol Int. 2012;19(2):207-14. https://doi. org/10.4103/0971-6580.97224 PMid:22778522

Al-Allaf LI, Al-Ashoo HA. The effects of imatinib on the testicular histology in male rats administered at peripubertal period. JABHS. 2014;15(1):24-34.

Gado AM, Adam AI, Aldahmash BA. Cardiotoxicity induced by cyclophosphamide in rats: Protective effect of curcumin. J Res Environ Sci Toxicol. 2013;2(4):87-95.

Chintalgattu V, Khakoo AY. Cardiovascular toxicities due to molecularly targeted cancer therapeutics. Clin Adv Hematol Oncol. 2010;8(2):133-5.

Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med. 2005;353(2):172-87. https://doi.org/10.1056/NEJMra044389 PMid:16014887

Cohen MH, Johnson JR, Pazdur R. U.S. Food and drug administration drug approval summary: Conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval. Clin Cancer Res. 2005;11(1):12-9. PMid:15671523

Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006;12(8):908-16. https://doi.org/10.1038/nm1446 PMid:16862153

Schellings MW, Lowenberg B, Pinto YM. Another look at imatinib mesylate. N Engl J Med. 2007;356(11):1183. https://doi.org/10.1056/nejmc063721 PMid:17361003

Mauro MJ, Deininger MW. Management of drug toxicities in chronic myeloid leukaemia. Best Pract Res Clin Haematol.

;22(3):409-29. https://doi.org/10.1016/j.beha.2009.06.001 PMid:19959091

Jaiswal AK. Nrf2 signaling in coordinated activation of antioxidant gene expression. Free Radic Biol Med. 2004;36(10):1199-207. https://doi.org/10.1016/j.freeradbiomed.2004.02.074 PMid:15110384

Cheng H, Force T. Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics. Circ Res. 2010;106(1):21-34. https://doi.org/10.1161/CIRCRESAHA.109.206920 PMid:20056943

Kostin S. Pathways of myocyte death: Implication for development of clinical laboratory biomarkers. Adv Clin Chem. 2005;40:37-98. https://doi.org/10.1016/s0065-2423(05)40002-5 PMid:16355920

Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370(9604):2011-9. https://doi.org/10.1016/S0140-6736(07)61865-0 PMid:18083403

Tiribelli M, Colatutto A, Marin L, Barbina G, Qualizza U, Damiani D, et al. Brain natriuretic peptide level as a marker of cardiac function in imatinib-treated chronic myeloid leukemia patients: No evidence of cardiotoxicity of imatinib therapy. Am J Hematol. 2008;83(6):517-8. https://doi.org/10.1002/ajh.21157 PMid:18306359

Li B, Wang X, Rasheed N, Hu Y, Boast S, Ishii T, et al. Distinct roles of c-Ab1 and Atm in oxidative stress response are mediated by protein kinase C delta. Genes Dev. 2004;18(5):1824-37. https://doi.org/10.1101/gad.1223504 PMid:15289456

Nilsson I, Shibuya NM, Wennstrom S. Differential activation of vascular genes by hypoxia in primary endothelial cells. Exp Cell Res. 2004;299(2):476-85. https://doi.org/10.1016/j.yexcr.2004.06.005 PMid:15350545

Hassan NA, Yousef MM. Study of imatinib cardiotoxicity in adult male rabbits. IOSR J Enviro Sci Toxicol Food Technol. 2013;6(5):14-26.

Wang S, Wilkes MC, Leof EB, Hirschberg R. Imatinib mesylate blocks a non-Smad TGF-β pathway and reduces renal fibrogenesis in vivo. FASEB J. 2009;19(1):1-11. https://doi.org/10.1096/fj.04-2370com PMid:15629889

Rosenbloom J, Castro SV, Jimenez SA. Narrative review: Fibrotic diseases: Cellular and molecular mechanisms and novel therapies. Ann Intern Med. 2010;152(3):159-66. https://doi.org/10.7326/0003-4819-152-3-201002020-00007 PMid:20124232